NEW YORK (GenomeWeb News) – Accelr8 today said fiscal second-quarter revenues rose 53 percent as R&D spending decreased 57 percent and losses narrowed 42 percent.
 
Total receipts for the three months ended Jan. 31 increased to $85,000 from 55,000 year over year.
 
More than half the revenues came from license fees, with smaller amounts coming from option fees and from OptiChem sales.
  
R&D spending fell to $250,000 from $570,000 year over year.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.